Glenmark Pharmaceuticals (NSE:GLENMARK) Beneish M-Score: -2.31 (As of Jun. 30, 2026)


NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
86 GF Score
Price ₹2,186.60
GF Value ₹1,988.54
Valuation Fairly Valued
View Full Analysis

What is Glenmark Pharmaceuticals Beneish M-Score?

Glenmark Pharmaceuticals NSE:GLENMARK +1.49% 86 Beneish M-Score is -2.31 as of Jun. 30, 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 86/100 and a GF Value™ of ₹1,988.54 (Fairly Valued). Among 908 Drug Manufacturers companies, Glenmark Pharmaceuticals ranks worse than 64.32% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.31 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Glenmark Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NSE:GLENMARK' s Beneish M-Score Range Over the Past 10 Years
Min: -3.24   Med: -2.46   Max: -1.5
Current: -2.31

During the past 13 years, the highest Beneish M-Score of Glenmark Pharmaceuticals was -1.50. The lowest was -3.24. And the median was -2.46.


Glenmark Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Beneish M-Score Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.28 -2.47 -3.24 -1.50 -2.31

Glenmark Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.50 0.00 0.00 0.00 -2.31

NSE:GLENMARK vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Beneish M-Score falls into.


NSE:GLENMARK
86GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Glenmark Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1578+0.528 * 0.9342+0.404 * 1.2069+0.892 * 1.2712+0.115 * 0.9477
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.104641-0.327 * 0.83
=-2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹49,634 Mil.
Revenue was ₹167,114 Mil.
Gross Profit was ₹119,639 Mil.
Total Current Assets was ₹112,997 Mil.
Total Assets was ₹199,079 Mil.
Property, Plant and Equipment(Net PPE) was ₹43,174 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹5,735 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹63,764 Mil.
Long-Term Debt & Capital Lease Obligation was ₹4,863 Mil.
Net Income was ₹13,619 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹34,450 Mil.
Total Receivables was ₹33,723 Mil.
Revenue was ₹131,458 Mil.
Gross Profit was ₹87,925 Mil.
Total Current Assets was ₹92,955 Mil.
Total Assets was ₹160,496 Mil.
Property, Plant and Equipment(Net PPE) was ₹38,879 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4,860 Mil.
Selling, General, & Admin. Expense(SGA) was ₹16,033 Mil.
Total Current Liabilities was ₹59,670 Mil.
Long-Term Debt & Capital Lease Obligation was ₹6,989 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(49633.54 / 167114.03) / (33722.54 / 131458.36)
=0.297004 / 0.256526
=1.1578

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(87924.94 / 131458.36) / (119639.4 / 167114.03)
=0.668843 / 0.715915
=0.9342

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (112997.09 + 43174.42) / 199078.76) / (1 - (92954.65 + 38878.52) / 160495.54)
=0.215529 / 0.178587
=1.2069

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=167114.03 / 131458.36
=1.2712

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4860.1 / (4860.1 + 38878.52)) / (5734.81 / (5734.81 + 43174.42))
=0.111117 / 0.117254
=0.9477

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 167114.03) / (16032.88 / 131458.36)
=0 / 0.121962
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4863.07 + 63764.26) / 199078.76) / ((6989.1 + 59670.24) / 160495.54)
=0.344725 / 0.415335
=0.83

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(13618.51 - 0 - 34450.28) / 199078.76
=-0.104641

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Glenmark Pharmaceuticals has a M-score of -2.31 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.31 mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Beneish M-Score of -2.31 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Glenmark Pharmaceuticals and its competitors. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #584 out of 908 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Glenmark Pharmaceuticals' Beneish M-Score too high?
Glenmark Pharmaceuticals' current Beneish M-Score is -2.31. Based on the distribution chart, Glenmark Pharmaceuticals ranks #584 out of 908 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Glenmark Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #584 out of 908 companies for Beneish M-Score. This places Glenmark Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Beneish M-Score is -2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,988.54, compared to a current price of ₹2,186.60 — trading 10% above its estimated fair value. The current Beneish M-Score is -2.31. Glenmark Pharmaceuticals' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Beneish M-Score is -2.31 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,186.60 is trading 10% above its estimated GF Value™ of ₹1,988.54. GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLENMARK:

  • Beneish M-Score: -2.31
  • GF Value™: ₹1,988.54 vs. price of ₹2,186.60 (10% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
86GF Score

Get the complete analysis for NSE:GLENMARK

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,186.60
Price
₹1,988.54
GF Value